These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2761048)

  • 21. [Reevaluation of indications for adjuvant hormone therapy in primary breast cancer with high metastatic risk].
    Martin PM; Romain S; Spyratos F; Spitalier JM; Ayme Y; Brandone H; Bressac C; Hans D; Jacquemier J; Hacene K
    Bull Cancer; 1991; 78(8):709-23. PubMed ID: 1932838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Adjuvant therapies in breast carcinoma].
    Joss R; Brunner K
    Schweiz Rundsch Med Prax; 1991 Mar; 80(11):247-54. PubMed ID: 2024099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor stem cells and the curability of early human breast cancer.
    Jasmin C
    Recent Results Cancer Res; 1993; 127():7-12. PubMed ID: 8502832
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent trends in the management of breast cancer. 3. Controversies in the use of adjuvant chemotherapy, hormonotherapy and radiotherapy for breast cancer.
    Donegan WL
    Can J Surg; 1992 Aug; 35(4):371-7. PubMed ID: 1498737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
    Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W;
    J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controversies in the medical management of breast cancer.
    Smith IE
    Postgrad Med J; 1985 Feb; 61(712):117-22. PubMed ID: 3983039
    [No Abstract]   [Full Text] [Related]  

  • 27. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
    Benson JR
    J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
    [No Abstract]   [Full Text] [Related]  

  • 29. Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer.
    Wolff AC; Davidson NE
    J Clin Oncol; 2006 Nov; 24(31):4949-51. PubMed ID: 17075110
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of early-stage breast cancer. Many questions, a few answers.
    Laughlin EH
    Ala Med; 1991 Apr; 60(10):10-4. PubMed ID: 1862754
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
    Bezwoda WR; Derman DP; Browde S; Goss G; Lange M
    S Afr Med J; 1984 Sep; 66(10):372-4. PubMed ID: 6484759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases].
    Roy JA; Piccart MJ
    Rev Med Brux; 1995; 16(4):242-4. PubMed ID: 7481234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Value of thymidine kinase in the prediction of response to treatment by chemotherapy or hormone therapy in breast cancer].
    Bennini N; Mauriac L; Wafflart J; Bonichon F; Durand M
    Bull Cancer; 1992; 79(8):773-9. PubMed ID: 1467600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant systemic treatment of resectable breast cancer: eleven years results of a monoinstitutional chemo-hormone-immunotherapy trial.
    Rosso R; Boccardo F; Brema F; Sertoli MR; Amoroso D; Bertelli G; Pronzato P
    Anticancer Res; 1989; 9(4):1153-6. PubMed ID: 2817796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant hormone treatment and chemotherapy in postmenopausal women with operable breast cancer: a retrospective analysis.
    Oriana S; Coradini D; Sasso GM; Di Fronzo G
    Anticancer Res; 1991; 11(6):2199-205. PubMed ID: 1776861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
    Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant therapy for node-negative breast cancer: a cautious interpretation.
    Henderson IC
    Important Adv Oncol; 1990; ():199-216. PubMed ID: 1691137
    [No Abstract]   [Full Text] [Related]  

  • 38. Systemic adjuvant therapy for breast cancer.
    Reed EC
    Nebr Med J; 1996 Mar; 81(3):48-50. PubMed ID: 8907820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Sequencing of adjuvant treatment after surgery for invasive breast cancer].
    Petit T; Claude L; Carrie C
    Cancer Radiother; 2004 Feb; 8(1):54-8. PubMed ID: 15093202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy and hormone therapy of metastatic breast cancer.
    Paterson AH
    Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):631-3. PubMed ID: 3835708
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.